Nearly 200 years after the introduction of the stethoscope, the accuracy of a pocket ultrasound device that enables a physician to “look” at a patient’s heart during routine physical exams has been validated for the first time in peer-reviewed research led by Scripps Translational Science Institute (STSI) and Scripps Health.
Roughly the size of a smart phone, the Vscan™ pocket ultrasound used for point of care assessment of heart health could significantly reduce costs from traditional echocardiograms and improve the quality of care. Research was published in the July 5 issue of the Annals of Internal Medicine.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50963-vscan-pocket-ultrasound-echocardiogram-stethoscope
Bayer HealthCare’s Consumer Care division announced today the introduction of Bayer® Advanced Aspirin, the next generation of aspirin for pain relief. Using the patent-pending Pro-Release™ Technology, Bayer Advanced Aspirin is clinically proven to relieve tough pain twice as fast as previous Bayer® Aspirin tablets.
With the introduction of aspirin in 1899, Bayer offered one of the first widely accessible analgesics, or pain relievers, to consumers. Today, Bayer's overall global Aspirin business continues to grow, and had double-digit, year-on-year sales growth in Q1 2011. Yet, while Bayer continues to be a leader in the category, for many U.S. consumers, Bayer Aspirin is primarily synonymous with cardiovascular use. Now, through a combination of technological innovation and rich analgesic heritage, Bayer is introducing a new standard in aspirin for tough pain relief with Bayer Advanced Aspirin.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bayer/50414/
New data revealed that nearly 100 percent (99%) of 200 U.S. primary care physicians surveyed agree that heart disease and stroke are the number one cause of death and disability among type 2 diabetes patients; however, almost 40 percent (36%) of these physicians underestimate the number of patients who die from cardiovascular disease. Furthermore, while people with diabetes are two to four times more likely to have heart disease than people without diabetes, the survey, conducted by Harris Interactive and supported by Merck, found only one out of five (21%) patients (n=664) listed heart attack or heart failure as their biggest worry regarding diabetes complications, and even fewer patients (7%) listed stroke.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/merck/50638/
A new survey from the nonprofit Gout & Uric Acid Education Society (GUAES) highlights an alarming awareness gap among Americans regarding the risk factors for gout, a chronic, potentially disabling form of arthritis which now affects an estimated 8.3 million Americans. Among the survey findings are that only one in 10 Americans correctly cited cardiovascular disease as a risk factor for gout, while only one in three Americans correctly reported that obesity is a risk factor, and less than one in five reported that diabetes and kidney disease are risk factors. GUAES released the survey findings in advance of its annual Gout Awareness Day on May 22.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/gouteducation/49664/
Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare professionals better educate patients and caregivers about therapy options related to cardiovascular and peripheral diseases, specifically atrial and ventricular arrhythmias, coronary artery disease, heart failure, heart rhythm disorders and peripheral vascular disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43509-boston-scientific-cardioteach-ipad-app
C. R. Bard, Inc. today announced the publication of RESILIENT trial results by Circulation: Cardiovascular Interventions showing the Bard LifeStent® Vascular Stent improved patency and reduced revascularization rates in patients with moderate-length lesions in the superficial femoral artery (SFA) and proximal popliteal artery compared to patients treated with percutaneous transluminal angioplasty (PTA).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bard/44623/
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
A study conducted by researchers from the University of L’Aquila in Italy and Mars, Incorporated provides compelling new evidence that the regular consumption of dietary cocoa flavanols may improve cognitive function in elderly subjects with early memory decline. Just published online in the journal Hypertension, this current study significantly advances understanding of the benefits of flavanols by specifically exploring the impact of regular cocoa flavanol consumption on cognitive function in a population with Mild Cognitive Impairment (MCI). Previous research has suggested that the benefits of cocoa flavanols could extend to the brain. However, these studies were either only short-term or did not demonstrate a consistent cognitive benefit. This unique study addresses this gap and provides important insights into the possibility of slowing or even reversing cognitive declines associated with aging through consumption of these natural compounds.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/marsincorporated/56580/
Melissa d’Arabian – celebrity chef, TV host and busy mother of four – and Dr. William Castelli – renowned cardiovascular specialist and former Director of the Framingham Heart study – announced today the launch of Get Real About Seafood, an educational campaign to raise awareness about the heart and brain health benefits of seafood and provide resources to help people eat a seafood-rich diet. On average, Americans eat about half the recommended 2 to 3 seafood servings each week due to a lack of understanding about health benefits and lack of confidence in selecting or preparing seafood.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55945-melissa-d-arabian-and-doctor-william-castelli-get-real-about-seafood
Back App proven to improve back pain and prevent office workers from falling victim to Sitting Disease, is a chair that is very different from all others.
Back pain is a modern epidemic, with recent high profile victims including UK Prime Minister David Cameron, model Jodie Kidd and tennis ace Andy Murray.
With 80% of people experiencing some form of back pain in their lifetime and the rise of tablet computers creating a generation hunched over screens - dubbed the ‘iPosture’ generation – the Back App is more relevant than ever in the effort to combat Sitting Disease which, in addition to back pain, has been linked to cardiovascular illness and cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/51361-back-app-guarantee-improved-back-pain
According to the results of a recent study conducted by researchers at the USDA-Agricultural Research Service Western Human Nutrition Research Center, the Northwest Cherry Growers are pleased to announce that consuming about 45 (280 g) sweet Bing cherries significantly decreased circulating concentrations of specific inflammatory biomarkers in the blood. According to Dr. Kent Erickson, Professor at UC Davis School of Medicine and a collaborator in the study, “Many studies by other investigators have demonstrated that some of those inflammation markers are associated with increased risk for some chronic diseases such as cardiovascular disease, diabetes, and cancer.” The findings of the study have been published in the March 2013 issue of The Journal of Nutrition.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61851-northwest-cherries-usda-study-health-benefits
Leading scientists have released the latest results of the large scale trials related to nuts consumption and health, particularly in myocardial infarction, stroke and cardiovascular diseases. Recent scientific studies show the benefits of regular intake of nuts, not only associated with cardiovascular health but also with renal function, diabetes, cognitive function, atherosclerosis, metabolic syndrome, inflammatory biomarkers, etc. It is important to highlight that scientific evidence demonstrates that eating nuts is not associated with a higher risk of weight gain, and even reinforce their importance as sources of key nutrients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62432-scientifically-proven-nuts-are-not-fattening
